CD133 (Uchida et al., 2000), a cell-surface epitope enriched in NSCs, was also used in critical functional studies that isolated a subset of GBM cells with enhanced tumour-initiation capacity compared to the CD133-negative population (Singh et al., 2004). This evidence concerns the gene PROM1 and neoplasm.